Prices are updated after-hours
  Health Technology Neurological

nasdaq:SIOX Sio Gene Therapies Inc

SIOX | $0.478 -20.5% 40K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (16.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (84.8% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 35,360,144
http://www.siogtx.com
 Sec Filling | Patents | 38 employees


(United Kingdom) Sio Gene Therapies Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. Axovant operates through seven wholly owned subsidiaries and also has business operations in Basel, Switzerland and New York, NY. The company was founded on October 31, 2014 and is headquartered in New York, NY.
acquisitions   gene therapies   parkinson   neurological  

add to watch list Paper trade email alert is off

nasdaq:ATHX Athersys, Inc.

ATHX | $0.1018 -40.86% 95M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (-89.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (46.93% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 2,290,644
http://www.athersys.com
 Sec Filling | Patents | 83 employees


(US) Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.
cardiovascular   stem cell   urea   t-cell   neurological   ceiling  

add to watch list Paper trade email alert is off

nasdaq:FWP Forward Pharma A/S

FWP | $1.95 7.74% 7.18% twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-64.55% volume)
Earnings Calendar:
Market Cap: $ 13,827,811
http://www.forward-pharma.com
 Sec Filling | Patents | 5 employees


(DK) Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company was founded by Florian Schönharting on July 1, 2005 and is headquartered in Copenhagen, Denmark.
neurological   treatment  

add to watch list Paper trade email alert is off

nasdaq:NTUS Natus Medical Incorporated

NTUS | $32.96 0.09% 0.0% twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2022-08-04
Market Cap: $ 1,139,798,659
http://www.natus.com
 Sec Filling | Patents | 1484 employees


Natus Medical, Inc. provides medical device solutions focuses on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages. Its products are used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, sleep disorders, neuromuscular diseases and balance and mobility disorders. The company was founded by Maurizio Liverani, John Robert Camber Porter, William New, Jr., Brian Prinn and William W. Moore on May 26, 1987 and is headquartered in Pleasanton, CA.
diagnostics   neurological   treatment  

add to watch list Paper trade email alert is off

nasdaq:BTAI BioXcel Therapeutics, Inc.

BTAI | $2.77 8.63% 7.94% 620K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-8.3% 1m) (-87.9% 1y) (0.0% 2d) (0.0% 3d) (-7.3% 7d) (6.43% volume)
Earnings Calendar: 2024-03-12
Market Cap: $ 84,697,379
http://www.bioxceltherapeutics.com
 Sec Filling | Patents | 24 employees


(United States) BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
cancer   prostate cancer   pancreatic   neurological   treatment  

add to watch list Paper trade email alert is off

nasdaq:ADXN Addex Therapeutics Ltd

ADXN | News | $19.0 -9.35% -10.32% 20K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (85.2% 1m) (63.8% 1y) (0.0% 2d) (0.0% 3d) (-8.7% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 29,189,453
http://www.addextherapeutics.com
 Sec Filling | Patents | 63 employees


(CH) Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.
neurological  

add to watch list Paper trade email alert is off

nasdaq:NBSE NeuBase Therapeutics, Inc.

NBSE | $0.411 -5.21% -5.5% 89K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-60.7% 1m) (-86.9% 1y) (0.0% 2d) (0.0% 3d) (0.7% 7d) (-54.73% volume)
Earnings Calendar: 2022-12-22
Market Cap: $ 1,541,903
http://www.neubasetherapeutics.com
 Sec Filling | Patents | 9 employees


(US) NeuBase Therapeutics, Inc. engages in the development of drugs for patients with genetic neurological disorder. Its pipelines include Huntington’s Disease, NT0100 Program - PATrOL Enabled gamma-PNA for Huntington's Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy. The company was founded by Dietrich A. Stephan on August 28, 2018 and is headquartered in Pittsburgh, PA.
genetic   neurological  

add to watch list Paper trade email alert is off

nasdaq:ASRT Assertio Holdings, Inc.

ASRT | $0.7625 1.13% 1.11% 890K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-23.5% 1m) (-86.7% 1y) (0.0% 2d) (0.0% 3d) (-2.3% 7d) (-34.99% volume)
Earnings Calendar: 2024-03-11
Market Cap: $ 72,437,500
http://www.assertiotx.com
 Sec Filling | Patents | 125 employees


Assertio Holdings, Inc. operates as a holding company. The firm develops pharmaceuticals. It engages in the provision of solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.
urea   neurological   msa  

add to watch list Paper trade email alert is off

nasdaq:NBIX Neurocrine Biosciences, Inc.

NBIX M | $132.03 -0.39% -0.39% 560K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-5.3% 1m) (27.4% 1y) (0.0% 2d) (0.0% 3d) (-1.1% 7d) (-44.73% volume)
Earnings Calendar: 2024-02-07
Market Cap: $ 13,137,909,210
http://www.neurocrine.com
 Sec Filling | Patents | 700 employees


(US) Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.
endocrine   neurological   msa   treatment  

Drugs
INGREZZA (Valbenazine)
ONGENTYS (opicapone)

add to watch list Paper trade email alert is off

nyse:ABBV AbbVie Inc.

ABBV | $166.41 1.06% 0.0% 5.5M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-7.3% 1m) (2.1% 1y) (0.0% 2d) (0.8% 3d) (2.2% 7d) (NaN% volume)
Earnings Calendar:
Market Cap: $ 294,653,364,441
http://www.abbvie.com
 Sec Filling | Patents | 30000 employees


AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
cancer   hiv   autoimmunity   hepatitis   fibrosis   metabolic   parkinson   neurological  

Drugs
Alcohol - Hand Sanitizer (Alcohol)
Androgel (Testosterone)
Creon (Pancrelipase)
Depakote (Divalproex Sodium)
Depakote ER (Divalproex Sodium)
Depakote Sprinkles (Divalproex Sodium)
Duopa (Carbidopa and Levodopa)
Gengraf (Cyclosporine)
Humira (Adalimumab)
Kaletra (Lopinavir and Ritonavir)
K-Tab (Potassium Chloride)
Lupaneta Pack (leuprolide acetate and norethindrone acetate)
Lupron Depot (leuprolide acetate)
Lupron Depot-PED (leuprolide acetate)
Marinol (Dronabinol)
Mavyret (Glecaprevir and Pibrentasvir)
Niaspan (Niacin)
Nimbex (Cisatracurium besylate)
Norvir (Ritonavir)
Oriahnn (Elagolix and Estradiol and Norethisterone)
Orilissa (Elagolix)
Rinvoq (Upadacitinib)
Skyrizi (Risankizumab-rzaa)
Survanta (Beractant)
Synthroid (Levothyroxine Sodium)
Tarka (Trandolapril and Verapamil Hydrochloride)
Tricor (Fenofibrate)
Trilipix (Fenofibric Acid)
Ultane (Sevoflurane)
Venclexta (Venetoclax)
Viekira Pak (Dasabuvir and Ombitasvir and Paritaprevir and Ritonavir)
Zemplar (Paricalcitol)

add to watch list Paper trade email alert is off

nasdaq:ITCI Intra-Cellular Therapies Inc.

ITCI 1 d | $72.29 0.4% 0.4% 2.2M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (10.4% 1m) (22.0% 1y) (0.0% 2d) (-4.8% 3d) (13.1% 7d) (NaN% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 6,998,191,837
http://www.intracellulartherapies.com
 Sec Filling | Patents | 330 employees


Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.
neurodegenerative   schizophrenia   glass   alzheimer   heavy drug   nervous system   neuropsychiatric   molecule drugs   neurological   msa   treatment   alzheimer’s  

add to watch list Paper trade email alert is off

nyse:BHVN Biohaven Pharmaceutical Holding Company Ltd.

BHVN 1 d | $38.99 -7.52% 0.0% 3.4M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-29.0% 1m) (199.0% 1y) (0.0% 2d) (-3.9% 3d) (-5.8% 7d) (Infinity% volume)
Earnings Calendar:
Market Cap: $ 3,189,663,547
http://www.biohavenpharma.com
 Sec Filling | Patents | 647 employees


(US) Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.
neurological  

add to watch list Paper trade email alert is off

nyse:BHC Bausch Health Companies Inc.

BHC | $8.69 1.05% 0.0% 2.9M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-8.9% 1m) (13.7% 1y) (0.0% 2d) (0.0% 3d) (1.3% 7d) (-8.18% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 3,137,000,875
http://www.bauschhealth.com
 Sec Filling | Patents | 21700 employees


Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.
glass   urea   aesthetic   women   brands   neurological  

add to watch list Paper trade email alert is off

nasdaq:SUPN Supernus Pharmaceuticals, Inc.

SUPN | $29.43 1.94% 1.9% 360K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-17.2% 1m) (-22.9% 1y) (0.0% 2d) (-0.4% 3d) (-3.7% 7d) (-11.66% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 1,610,849,755
http://www.supernus.com
 Sec Filling | Patents | 464 employees


(US) Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
nervous system   neurological   treatment   3d  

Drugs
OXTELLAR XR (OXCARBAZEPINE)
Trokendi XR (topiramate)

add to watch list Paper trade email alert is off

nasdaq:CPRX Catalyst Pharmaceuticals, Inc.

CPRX | $15.12 -1.43% -1.46% 7.4M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-8.1% 1m) (-5.8% 1y) (0.0% 2d) (0.0% 3d) (1.0% 7d) (-29.07% volume)
Earnings Calendar: 2024-02-28
Market Cap: $ 1,784,327,711
http://www.catalystpharma.com
 Sec Filling | Patents | 76 employees


(US) Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.
antibody   neurological  

Drugs
Firdapse (amifampridine phosphate)

add to watch list Paper trade email alert is off

nasdaq:BIIB Biogen Inc.

BIIB | $194.39 2.03% 1.99% 1.6M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-10.5% 1m) (-32.8% 1y) (0.0% 2d) (0.0% 3d) (-0.8% 7d) (-24.78% volume)
Earnings Calendar: 2024-02-13
Market Cap: $ 28,256,685,523
http://www.biogen.com
 Sec Filling | Patents | 7400 employees


(US) Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
sclerosis   neurodegenerative   multiple sclerosis   neurological   treatment  

Drugs
ALPROLIX (Coagulation Factor IX (Recombinant), Fc Fusion Protein)
AVONEX (interferon beta-1a)
Plegridy (peginterferon beta-1a)
Plegridy Pen (peginterferon beta-1a)
Spinraza (Nusinersen)
Tecfidera (dimethyl fumarate)
TECFIDERA (dimethyl fumarate)
TYSABRI (natalizumab)
Vumerity (diroximel fumarate)

add to watch list Paper trade email alert is off

nasdaq:OVID Ovid Therapeutics Inc.

OVID | $3.245 1.09% 1.08% 180K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (15.1% 1m) (5.2% 1y) (0.0% 2d) (3.2% 3d) (0.3% 7d) (41.42% volume)
Earnings Calendar: 2024-03-11
Market Cap: $ 229,453,486
http://www.ovidrx.com
 Sec Filling | Patents | 59 employees


(US) Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.
covid   neurological  

add to watch list Paper trade email alert is off

nasdaq:VRTX Vertex Pharmaceuticals Incorporated

VRTX | News | $394.43 0.24% 0.24% 1.3M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-4.2% 1m) (20.0% 1y) (0.0% 2d) (0.5% 3d) (-0.6% 7d) (NaN% volume)
Earnings Calendar: 2024-02-05
Market Cap: $ 101,944,118,659
http://www.vrtx.com
 Sec Filling | Patents | 3000 employees


(US) Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
sclerosis   cancer   battery   batteries   autoimmunity   infectious disease   multiple sclerosis   rheumatoid arthritis   influenza   fibrosis   molecule drugs   neurological   treatment   injection  

Drugs
Kalydeco (ivacaftor)
ORKAMBI (lumacaftor and ivacaftor)
SYMDEKO (Tezacaftor and Ivacaftor)
Trikafta (Elexacaftor, Tezacaftor, and Ivacaftor)

add to watch list Paper trade email alert is off

nasdaq:HSDT Helius Medical Technologies, Inc.

HSDT | $5.01 -1.96% -2.0% 4.5K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-8.8% 1m) (-50.7% 1y) (0.0% 2d) (0.0% 3d) (-11.0% 7d) (-37.95% volume)
Earnings Calendar:
Market Cap: $ 4,445,348
http://www.heliusmedical.com
 Sec Filling | Patents | 19 employees


Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational Portable Neuromodulation Stimulator (PoNS), that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.
education   neurological  

add to watch list Paper trade email alert is off

nasdaq:TRVI Trevi Therapeutics, Inc.

TRVI | $2.82 5.03% 4.79% 140K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-24.0% 1m) (-1.1% 1y) (0.0% 2d) (4.3% 3d) (-4.3% 7d) (-28.37% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 194,467,671
http://www.trevitherapeutics.com
 Sec Filling | Patents | 17 employees


Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.
chronic cough   fibrosis   parkinson   neurological   treatment  

add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlist
Gainers vs Losers
67% 33%

Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M twitter stocktwits trandingview |
Finance
EGOX | $0.0515 43.06% 30.1% 330M twitter stocktwits trandingview |

OLB 4 | $0.33 -14.95% 25.53% 840K twitter stocktwits trandingview |
Technology Services
NVFY | $2.77 31.28% 23.83% 33M twitter stocktwits trandingview |
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M twitter stocktwits trandingview |
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M twitter stocktwits trandingview |
Distribution Services
INSG | $3.03 25.21% 20.13% 330K twitter stocktwits trandingview |
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K twitter stocktwits trandingview |
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M twitter stocktwits trandingview |

ASNS | $0.828 21.75% 17.86% 18K twitter stocktwits trandingview |

Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M twitter stocktwits trandingview |
n/a
 | 23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M twitter stocktwits trandingview |
Finance
 | 22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K twitter stocktwits trandingview |
Health Technology
 | 22:30
BCDA P 2750 | $0.377 -1.4% 97K twitter stocktwits trandingview |
Health Technology
 | 22:00
RMCF | $3.67 3.38% 3.27% 11K twitter stocktwits trandingview |
Consumer Non-Durables
 | 20:10
12 months watchlist earnings calendar